3-aminobenzylamine hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-aminobenzylamine hydrochloride
• 英文别名: m-aminobenzylamine hydrochloride；3-(aminomethyl)aniline;hydrochloride
• 化学式: C₇H₁₀N₂*ClH
• 分子量: 158.631
• InChiKey: AJHGEZFKLFWGEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.15
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-aminobenzylamine hydrochloride 在 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 (3aR,4R,6S,6aS)-4-[6-[(3-acetamidophenyl)methylamino]purin-9-yl]-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide
  参考文献：
  名称：

  Structure-Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists

  摘要：

  Adenosine analogues modified at the 5'-position as uronamides and/or as N-6-benzyl derivatives were synthesized. These derivatives were examined for affinity in radioligand binding assays at the newly discovered rat brain A(3) adenosine receptor and at rat brain A(1) and Az, receptors. 5'Uronamide substituents favored AS selectivity in the order N-methyl > N-ethyl approximate to unsubstituted carboxamide > N-cyclopropyl. 5'-(N-Methylcarboxamido)-N-6-benzyladenosine was 37-56-fold more selective for Ag receptors. Potency at A(3) receptors was enhanced upon substitution of the benzyl substituent with nitro and other groups. 5'-N-Methyluronamides and N-6-(3-substituted-benzyl) adenosines are optimal for potency and selectivity at A(3) receptors. A series of 3-(halobenzyl)5'-N-ethyluronamide derivatives showed the order of potency at A(1) and A(2)a receptors of I similar to Br > Cl > F. At A(3) receptors the 3-F derivative was weaker than the other halo derivatives. 5'-N-Methyl-N-6- (3-iodobenzyl) adenosine displayed a K-i value of 1.1 nM at A(3) receptors and selectivity versus A(1) and A(2a), receptors of 50-fold. A series of methoxybenzyl derivatives showed that a C-methoxy group best favored A(3) selectivity. A 4-sulfobenzyl derivative was a specific ligand at A(3) receptors of moderate potency. An aryl amino derivative was prepared as a probe for radioiodination and receptor cross-linking.

  DOI：

  10.1021/jm00031a014
• 作为产物：
  描述：

  3-氨基苯甲醛 在 palladium 10% on activated carbon 盐酸 、 盐酸羟胺 、 氢气 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 3-aminobenzylamine hydrochloride
  参考文献：
  名称：

  EP2511283

  摘要：

  公开号：

文献信息

• Cobalt-Catalyzed and Lewis Acid-Assisted Nitrile Hydrogenation to Primary Amines: A Combined Effort
  作者：Kenan Tokmic、Bailey J. Jackson、Andrea Salazar、Toby J. Woods、Alison R. Fout

  DOI：10.1021/jacs.7b07368

  日期：2017.9.27

  The selective hydrogenation of nitriles to primary amines using a bench-stable cobalt precatalyst under 4 atm of H2 is reported herein. The catalyst precursor was reduced in situ using NaHBEt3, and the resulting Lewis acid formed, BEt3, was found to be integral to the observed catalysis. Mechanistic insights gleaned from para-hydrogen induced polarization (PHIP) transfer NMR studies revealed that the

  本文报道了在 4 个大气压的 H 2 下使用实验室稳定的钴预催化剂将腈选择性氢化成伯胺。使用 NaHBEt 3 原位还原催化剂前体，并且发现所形成的路易斯酸 BEt 3 是观察到的催化作用的组成部分。从对氢诱导极化 (PHIP) 转移 NMR 研究中收集到的机理见解表明，腈的成对氢化是通过 Co(I/III) 氧化还原过程进行的。
• Multicyclic bis-amide MMP inhibitors
  申请人：Powers Timothy

  公开号：US20060173183A1

  公开（公告）日：2006-08-03

  The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。
• Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
  申请人：Celltech Therapeutics Limited

  公开号：US06337335B1

  公开（公告）日：2002-01-08

  Compounds of formula (1) are described: and the salts, solvates, hydrates and N-oxides thereof, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings given in claim 1. The compounds are selective inhibitors of protein kinases, especially src-family protein kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.

  描述了化合物的化学式（1）：以及其盐、溶剂合物、水合物和N-氧化物，其中R1、R2、R3、R4、R5、R6和R7具有权利要求1中给定的含义。这些化合物是蛋白激酶的选择性抑制剂，特别是src家族蛋白激酶，并且可用于预防和治疗免疫性疾病、过度增殖性疾病以及其他认为不当的蛋白激酶作用可能起作用的疾病。
• N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF
  申请人：Shi Jiangong

  公开号：US20130045942A1

  公开（公告）日：2013-02-21

  The present invention provides N 6 -substituted adenosine derivatives and N 6 -substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

  本发明提供了N6-取代腺苷衍生物和N6-取代腺嘌呤衍生物，其制备方法，包括上述化合物的药物组合物，以及这些化合物在制造治疗失眠、惊厥、癫痫和帕金森病的药物和保健产品以及预防和治疗痴呆症中的用途。
• Ｎ６−置換アデノシン誘導体とＮ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
  申请人：中国医学科学院葯物研究所

  公开号：JP2015172077A

  公开（公告）日：2015-10-01

  【課題】鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整を行うこと。【解決手段】特定の化合物のグループから選択されることを特徴とする、Ｎ６−置換アデノシン誘導体またはＮ６−置換アデニン誘導体。 また、治療上有効な量の上記化合物と、薬学的に許容される担体とを少なくとも含有することを特徴とする、医薬組成物。 さらに、鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整において使用されることを特徴とする、上記化合物。【選択図】なし

  该专利涉及调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品的组合。解决方案特点在于选择自特定化合物组中的N6-取代腺苷诱导体或N6-取代腺嘌呤诱导体。此外，医药组合物特点在于至少包含治疗有效量的上述化合物和药学上可接受的载体。进一步，该化合物特点在于用于调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品。【选择图】无